title: Why Biotechâ€™s Rally Can Last This Time
source: Yahoo
date: 2025-10-13
url: https://finnhub.io/api/news?id=fe355e46fcea064ffc035772d22d9b0caba235c8daeffd0526075c68989e1f02
After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.  Whether the run continues will depend on several factors: continued funding, a predictable regulatory environment, positive trial results, and steady deal activity.  Asad Haider,  head of U.S. healthcare equity research at Goldman Sachs, notes that biotech had moved in lockstep with the Russell 2000 small-cap index for much of the year amid bets on the trajectory of interest rates.
